8 June 2018 - - San Diego, California-based non-prescription medicine and consumer care products company Innovus Pharmaceuticals, Inc. (OTCQB: INNV) has received approval by Health Canada of its product ProstaGorx as a natural health product for the relief of urologic symptoms associated with mild to moderate benign prostatic hyperplasia (BPH) including weak urine flow, incomplete voiding, and frequent urination, the company said.
An estimated 50% of men have histologic evidence of BPH by age 50 and 75% by age 80; in 40–50% of these men, BPH becomes clinically significant.
BPH was one of the ten most common, and costly, diseases in men older than 50 years of age in a recent study in the United States.
Innovus Pharma is engaged in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.